Sponsor content
180 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for APIXABAN-APX apixaban 2.5 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for APIXABAN-APX apixaban 5 mg film-coated tablet blister pack.
-
Australian public assessment report (AusPar)Augtyro has been approved for the treatment of adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OPDIVO SC nivolumab 600 mg in 5 mL (120 mg/mL) solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AUGTYRO repotrectinib 160 mg capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AUGTYRO repotrectinib 40 mg capsule bottle.
-
Australian public assessment report (AusPar)Inrebic (fedratinib as hydrochloride) has been approved for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
-
Prescription medicine registrationActive ingredients: repotrectinib.
-
Jul-2025Prescription medicine evaluationActive ingredient: deucravacitinib.
-
Prescription medicine registrationActive ingredients: nivolumab.